Dendreon (NASDAQ:DNDN) reported Q4 and FY 2010 earnings results Tuesday during the trading day, posting a disappointing loss of $0.64 per share for the quarter, a bigger loss than the $0.49 analysts were projecting on average. Net loss for the year was $439.5 million, or $3.18 per share versus a loss of $2.04 per share in 2009.
Revenue for the quarter was $25 million, compared to $21,000 for the same quarter in 2009. FY revenue came in at $48.1 million, compared to $100,000 the year before.
Mitchell H. Gold, M.D., president and chief executive officer, said, "As we look to 2011, it will be a year of both execution and a year of growth for Dendreon, all of which is designed with a single goal in mind: to help patients with cancer live longer and live better lives."